219671US0CONT Attorney Docket No. UTILITY Ken HASS First Inventor or Application Identifier PATENT APPLICATION ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS TRANSMITTAL CONTAINING THE SAME, AND METHODS OF USING THE SAME (Only for new nonprovisional applications under 37 CFR 1.53(b)) SIGMA-TAU HEALTHSCIENCE S.p.A. Assignee Name: Via Treviso, 4; 00040 Pomezia (RM), ITALY Assignee Address: Assistant Commissioner for Patents ADDRESS TO: **Box Patent Application** APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 ACCOMPANYING APPLICATION PARTS Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing) 7. Assignment Papers (cover sheet & document(s)) 8. ■ Application Data Sheet. See 37 CFR 1.76 18 **Total Sheets** 2. Specification Power of 37 C.F.R. §3.73(b) Statement 9. Attorney (when there is an assignee) 10. English Translation Document (if applicable) 3. Drawing(s) (35 U.S.C. 113) Total Sheets Copies of IDS Information Disclosure ☐ Citations Statement (IDS)/PTO-1449 12. Preliminary Amendment **Total Pages** Oath or Declaration \boxtimes White Advance Serial No. Postcard ☐ Newly executed (original or copy) a. Certified Copy of Priority Document(s) Copy from a prior application (37 C.F.R. §1.63(d)) (if foreign priority is claimed) (for continuation/divisional with box 17 completed) b. Applicant claims small entity status. Signed statement attached deleting inventor(s) named in See 37 CFR 1.27 the prior application, see 37 C.F.R. §1.63(d)(2) and Request for Priority 16. **⊠** Other: CD-ROM or CD-R in duplicate, large table or Computer 5. Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission 6. (if applicable, all necessary) ☐ Computer Readable Form (CRF) b. Specification or Sequence Listing on : ii. 🔲 Paper If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below: of prior application no.: 09/653,861 ☐ Continuation-in-part (CIP) ☐ Divisional □ Continuation Group Art Unit: 1615 Examiner: P. McQueeney Prior application information: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18. Amend the specification by inserting before the first line the sentence: ☐ Continuation-in-part (CIP) ☐ Division September 1, 2000, pending, which claims benefit of Serial No. 60/152,240 filed September 3, 1999, now abandoned, and Serial No. 60/158,245 filed Filed on 09/653,861 of application Serial No. October 8 1999, now abanonded. ☐ Which was published in English ☐ Which was not published in English Filed ☐ This application claims priority of provisional application Serial No. 19. CORRESPONDENCE ADDRESS



22850

(703) 413-3000 FACSIMILE: (703) 413-2220

	Registration No.	: 24,618
Name: Norman F. Oblon		: Feb 14, 2002
Signature: Sent St		
Name: Stephen G. Baxter, Ph.D.	Registration No.	: 32,884
Name: Stephen G. Baxter, Fil.D.		

Docket No.

219671US0CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Ken HASSEN

SERIAL NO:

New Application

FILING DATE: Herewith

FOR:

ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS

CONTAINING THE SAME, AND METHODS OF USING THE SAME

FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	14 - 20 =	0	× \$18 =	\$0.00
INDEPENDENT CLAIMS	4 - 3 =	1	× \$84 =	\$84.00
MULTIPLE DEPENDENT CLAIMS (If applicable) + \$280 =			\$0.00	
☐ LATE FILING OF DECLARATION + \$130 =		\$0.00		
BASIC FEE			\$740.00	
TOTAL OF ABOVE CALCULATIONS			\$824.00	
☐ REDUCTION BY 50% FOR FILING BY SMALL ENTITY			\$0.00	
☐ FILING IN NON-ENGLISH LANGUAGE		+ \$130 =	\$0.00	
☐ RECORDATION OF ASSIGNMENT + \$40 =			\$0.00	
			TOTAL	\$824.00

☐ Please charge Deposit Account No. <u>15-0030</u> in the amount of

A duplicate copy of this sheet is enclosed.

A check in the amount of

\$824.00

to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Stephen G. Baxter, Ph.D.

32,884 Registration No.

Date: Feb 14, 2002

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ken HASSEN

GAU:

EXAMINER:

SERIAL NO: FILED:

FOR:

ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING

THE SAME, AND METHODS OF USING THE SAME

REQUEST FOR PRIORITY

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

CI	D
ΩI	\mathbf{r}

- ☑ Full benefit of the filing date of U.S. Application Serial Number 09/653,861, filed September 1, 2000, is claimed pursuant to the provisions of 35 U.S.C. §120.
- ☑ Full benefit of the filing date of U.S. Provisional Applications Serial Numbers 60/152,240, filed September 3, 1999 and 60/158,245, filed October 8, 1999, is claimed pursuant to the provisions of 35 U.S.C. §119(e).
- ☐ Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

COUNTRY

APPLICATION NUMBER

MONTH/DAY/YEAR

; and

Certified copies of the corresponding Convention Application(s)

- will be submitted prior to payment of the Final Fee
- □ were filed in prior application Serial No.

- were submitted to the International Bureau in PCT Application Number
- Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.
- ☐ (A) Application Serial No.(s) were filed in prior application Serial No.
- (B) Application Serial No.(s) are submitted herewith
 - will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND, &NEUSTADT, P.O

filed

Oblon Norman F.

Registration No. 24,618

Stephen G. Baxter, Ph.D. 32,884 Registration No.

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/98)